Download PDF
Pneumologie 2017; 71(07): 460-474
DOI: 10.1055/s-0043-106160
Leitlinie
© Georg Thieme Verlag KG Stuttgart · New York

S2k-Leitlinie Idiopathische Lungenfibrose – Update zur medikamentösen Therapie 2017

German Guideline for Idiopathic Pulmonary Fibrosis – Update on Pharmacological Therapies 2017
Jürgen Behr
 1   Medizinische Klinik und Poliklinik V, Klinikum der Universität München und Asklepios Fachkliniken München-Gauting, Comprehensive Pneumology Center, Mitglied des Deutschen Zentrums für Lungenforschung
,
Andreas Günther
 2   Schwerpunkt Fibrosierende Lungenerkrankungen, Universitätsklinikum Gießen – Marburg, Standort Gießen, Justus-Liebig-Universität Gießen, sowie Agaplesion Pneumologische Klinik Waldhof-Elgershausen, University of Giessen Marburg Lung Center, Mitglied des Deutschen Zentrums für Lungenforschung
,
Francesco Bonella
 3   Schwerpunkt interstitielle und seltene Lungenkrankheiten, Ruhrlandklinik, Universitätsklinikum Essen
,
Klaus Geißler
 4   Patientenvertretung Lungenfibrose e.V., Essen
,
Dirk Koschel
 5   Abteilung Innere Medizin/Pneumologie, Fachkrankenhaus Coswig, Zentrum für Pneumologie, Allergologie, Beatmungsmedizin, Theoraxchirurgie
,
Michael Kreuter
 6   Zentrum für interstitielle und seltene Lungenerkrankungen, Pneumologie und Beatmungsmedizin, Thoraxklinik, Universitätsklinikum Heidelberg, Mitglied des Deutschen Zentrums für Lungenforschung
,
Antje Prasse
 7   Klinik für Pneumologie, Medizinische Hochschule Hannover und Clinical Research Center Fraunhofer Institut ITEM, Mitglied des Deutschen Zentrums für Lungenforschung
,
Nicolas Schönfeld
 8   Klinik für Pneumologie, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Berlin
,
Helmut Sitter
 9   Institut für Theoretische Chirurgie, Philipps-Universität Marburg
,
Joachim Müller-Quernheim
10   Klinik für Pneumologie, Department Innere Medizin, Medizinische Fakultät, Albert Ludwigs Universität, Freiburg
,
Ulrich Costabel
 3   Schwerpunkt interstitielle und seltene Lungenkrankheiten, Ruhrlandklinik, Universitätsklinikum Essen
› Author Affiliations
Further Information

Publication History

Publication Date:
30 May 2017 (online)

Also available at
   Permissions and Reprints

Corrected by:

S2k-Leitlinie Idiopathische Lungenfibrose – Update zur medikamentösen Therapie 2017Pneumologie 2017; 71(07): 474-474
DOI: 10.1055/s-0043-115504

Zusammenfassung

Die idiopathische Lungenfibrose (idiopathische pulmonale Fibrose, IPF) ist eine schwerwiegende Lungenerkrankung, die häufig innerhalb von zwei bis vier Jahren nach Diagnosestellung zum Tod führt. Seit Veröffentlichung der deutschen IPF-Leitlinie im Jahr 2013 liegen neue Therapiestudien vor, die eine Neubewertung der Behandlungsstrategien erfordern. Abweichend von der Vorgängerleitlinie wurde in der aktuellen Überarbeitung nicht mehr das GRADE-System sondern die Oxford Evidenzsystematik mit drei Empfehlungsgraden (A, B, C) verwendet, weil dieses System eine differenziertere Betrachtung erlaubt. Folgende Medikamente wurden mit dem Empfehlungsgrad A und dem Evidenzgrad 1-b als nicht geeignet für die Behandlung der IPF klassifiziert: Triple-Therapie aus Prednisolon, Azathioprin und Acetylcystein; Antikoagulation mit Vitamin-K-Antagonisten; Imatinib; Ambrisentan; Bosentan; Macitentan. Weniger eindeutig ist die negative Bewertung des Phosphodiesterase-5-Inhibitors Sildenafil und der Acetylcystein-Monotherapie (Empfehlungsgrad B, Evidenzgrad 2-b). Eindeutig positiv fiel die Empfehlung für Nintedanib und Pirfenidon zur Behandlung von IPF-Patienten aus (Empfehlungsgrad A, Evidenzgrad 1-a). Mit Empfehlungsgrad C und Evidenzgrad 4 wurde der generelle Einsatz von Antazida zur Behandlung der IPF als nicht zu empfehlen bewertet, da die Datenlage widersprüchlich ist; hier weicht die deutsche Leitlinie auch am deutlichsten von der internationalen Leitlinie ab. Am Ende der Leitlinie wird aus Expertensicht zu offenen Fragen in der Therapie der IPF Stellung genommen, für die bisher keine ausreichende Evidenzbasis existiert.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a severe and often fatal disease with a median survival of 2 – 4 years after diagnosis. Since the publication of the German IPF guideline in 2013 new treatment trials have been published, necessitating an update of the pharmacological therapy of IPF. Different from the previous guideline, the GRADE system was discarded and replaced by the Oxford evidence classification system which allows a more differentiated judgement. The following pharmacological therapies were rated not suitable for the treatment of IPF patients (recommendation A; evidence 1-b): triple therapy with prednisolone, azathioprine and acetyl-cysteine; imatinib; ambrisentan; bosentan; macitentan. A less clear but still negative recommendation (B, 1-b) was attributed to the treatment of IPF with the phosphodiesterase-5-inhibitor sildenafil and acetyl-cysteine monotherapy. In contrast to the international guideline antacid therapy as a general treatment for IPF was rated negative, based on conflicting results of recent analyses (recommendation C; evidence 4). An unanimous positive recommendation was granted for the antifibrotic drugs nintedanib and pirfenidone for the treatment of IPF (A, 1-a). For some open questions in the management of IPF patients for which firm evidence is lacking the guideline also offers recommendations based on expert consensus.

 

  • Literatur

  • 1 Behr J, Günther A, Ammenwerth W. et al. S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose. Pneumologie 2013; 67: 81-111
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Raghu G, Rochwerg B, Zhang Y. et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192: e3-e19
    CrossrefPubMedGoogle Scholar
  • 3 Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989; 139: 370-372
    CrossrefPubMedGoogle Scholar
  • 4 Behr J, Maier K, Degenkolb B. et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997; 156: 1897-1901
    CrossrefPubMedGoogle Scholar
  • 5 Demedts M, Behr J, Buhl R. et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl JMed 2005; 353: 2229-2242
    CrossrefPubMedGoogle Scholar
  • 6 Hunninghake GW. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2285-2287
    CrossrefPubMedGoogle Scholar
  • 7 Wells AU. Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled. Eur Respir J 2006; 27: 664-666
    CrossrefPubMedGoogle Scholar
  • 8 The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, Azathioprine, and N-Acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977
    CrossrefPubMedGoogle Scholar
  • 9 Idiopathic Pulmonary Fibrosis Clinical Research. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2093-2101
    CrossrefPubMedGoogle Scholar
  • 10 Oldham JM, Ma SF, Martinez FJ. et al. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. American journal of respiratory and critical care medicine 2015; 192: 1475-1482
    CrossrefPubMedGoogle Scholar
  • 11 Hubbard RB, Smith C, Le Jeune I. et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 2008; 178: 1257-1261
    CrossrefPubMedGoogle Scholar
  • 12 Sode BF, Dahl M, Nielsen SF. et al. Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med 2010; 181: 1085-1092
    CrossrefPubMedGoogle Scholar
  • 13 Kubo H, Nakayama K, Yanai M. et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-1482
    CrossrefPubMedGoogle Scholar
  • 14 Noth I, Anstrom KJ, Calvert SB. et al. A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2012; 186: 88-95
    CrossrefPubMedGoogle Scholar
  • 15 Kreuter M, Wijsenbeek MS, Vasakova M. et al. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur Respir J 2016; 47: 1776-1784
    CrossrefPubMedGoogle Scholar
  • 16 Hyldgaard C, Hilberg O, Muller A. et al. A cohort study of interstitial lung diseases in central Denmark. Respir Med 2014; 108: 793-799
    CrossrefPubMedGoogle Scholar
  • 17 Tomassetti S, Ruy JH, Gurioli C. et al. The effect of anticoagulant therapy for idiopathic pulmonary fibrosis in real life practice. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30: 121-127
    PubMedGoogle Scholar
  • 18 Daniels CE, Lasky JA, Limper AH. et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181: 604-610
    CrossrefPubMedGoogle Scholar
  • 19 Park SH, Saleh D, Giaid A. et al. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997; 156: 600-608
    CrossrefPubMedGoogle Scholar
  • 20 Raghu G, Behr J, Brown KK. et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Annals of internal medicine 2013; 158: 641-649
    CrossrefPubMedGoogle Scholar
  • 21 King Jr TE, Behr J, Brown KK. et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81
    CrossrefPubMedGoogle Scholar
  • 22 King Jr TE, Brown KK, Raghu G. et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92-99
    CrossrefPubMedGoogle Scholar
  • 23 Raghu G, Million-Rousseau R, Morganti A. et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 2013; 42: 1622-1632
    CrossrefPubMedGoogle Scholar
  • 24 Jackson RM, Glassberg MK, Ramos CF. et al. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung 2010; 188: 115-123
    CrossrefPubMedGoogle Scholar
  • 25 Zisman DA, Schwarz M, Anstrom KJ. et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363: 620-628
    CrossrefPubMedGoogle Scholar
  • 26 Han MK, Bach DS, Hagan PG. et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and rightsided ventricular dysfunction. Chest 2013; 143: 1699-1708
    CrossrefPubMedGoogle Scholar
  • 27 Richeldi L, Costabel U, Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087
    CrossrefPubMedGoogle Scholar
  • 28 Richeldi L, du Bois RM, Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082
    CrossrefPubMedGoogle Scholar
  • 29 Richeldi L, du Bois RM, Raghu G. et al. Online supplement to: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med DOI: 10.1056/NEJMoa1402584.
    CrossrefPubMedGoogle Scholar
  • 30 Richeldi L, Cottin V, du Bois RM. et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med 2016; 113: 74-79
    CrossrefPubMedGoogle Scholar
  • 31 Costabel U, Inoue Y, Richeldi L. et al. Efficacy of nintedanib in Idiopathic Pulmonary Fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 2016; 193: 178-185
    CrossrefPubMedGoogle Scholar
  • 32 Taniguchi H, Xu Z, Azuma A. et al. Subgroup analysis of Asian patients in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. Respirology 2016; 21: 1425-1430
    CrossrefPubMedGoogle Scholar
  • 33 Wuyts WA, Kolb M, Stowasser S. et al. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤50 % of Predicted Value. Lung 2016; 194: 739-743
    CrossrefPubMedGoogle Scholar
  • 34 Raghu G, Wells AU, Nicholson AG. et al. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med 2017; 195: 78-85
    CrossrefPubMedGoogle Scholar
  • 35 Kolb M, Richeldi L, Behr J. et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2016; DOI: 10.1136/thoraxjnl-2016-208710. [Epub ahead of print] PMID: 27672117
    CrossrefPubMedGoogle Scholar
  • 36 Bonella F, Kreuter M, Hagmeyer L. et al. Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respiration 2016; 92: 98-106
    CrossrefPubMedGoogle Scholar
  • 37 Canestaro WJ, Forrester SH, Raghu G. et al. Drug treatment of idiopathic pulmonary fibrosis: Systematic review and network meta-analysis. Chest 2016; 149: 756-766
    CrossrefPubMedGoogle Scholar
  • 38 Rochwerg B, Neupane B, Zhang Y. et al. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med 2016; 14: 18
    CrossrefPubMedGoogle Scholar
  • 39 Rogliani P, Calzetta L, Cavalli F. et al. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Pulm Pharmacol Ther 2016; 40: 95-103
    CrossrefPubMedGoogle Scholar
  • 40 Nakazato H, Oku H, Yamane S. et al. A novel antifibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 2002; 446: 177-185
    CrossrefPubMedGoogle Scholar
  • 41 Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 291: 367-373
    PubMedGoogle Scholar
  • 42 Iyer SNGG, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 289: 211-218
    PubMedGoogle Scholar
  • 43 Oku H, Shimizu T, Kawabata T. et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008; 590: 400-408
    CrossrefPubMedGoogle Scholar
  • 44 Raghu G, Johnson WC, Lockhart D. et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999; 159: 1061-1069
    CrossrefPubMedGoogle Scholar
  • 45 Azuma A, Nukiwa T, Tsuboi E. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047
    CrossrefPubMedGoogle Scholar
  • 46 Taniguchi H, Ebina M, Kondoh Y. et al. Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829
    CrossrefPubMedGoogle Scholar
  • 47 Noble PW, Albera C, Bradford WZ. et al. CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769
    CrossrefPubMedGoogle Scholar
  • 48 King Jr TE, Bradford WZ, Castro-Bernardini S. et al. ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092
    CrossrefPubMedGoogle Scholar
  • 49 Noble PW, Albera C, Bradford WZ. et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016; 47: 243-253
    CrossrefPubMedGoogle Scholar
  • 50 Lancaster L, Albera C, Bradford WZ. et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ open respiratory research 2016; 3: e000105
    CrossrefPubMedGoogle Scholar
  • 51 Albera C. et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J 2016; 48: 843-851
    CrossrefPubMedGoogle Scholar
  • 52 Bonella F, Wessendorf TE, Costabel U. Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis. Dtsch Med Wochenschr 2013; 138: 518-523
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Oltmanns U, Kahn N, Palmowski K. et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 2014; 88: 199-207
    CrossrefPubMedGoogle Scholar
  • 54 Loeh B, Drakopanagiotakis F, Bandelli GP. et al. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015; 191: 110-113
    CrossrefPubMedGoogle Scholar
  • 55 Raghu G, Amatto VC, Behr J. et al. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 2015; 46: 1113-1130
    CrossrefPubMedGoogle Scholar
  • 56 Lee JS, Ryu JH, Elicker BM. et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 1390
    CrossrefPubMedGoogle Scholar
  • 57 Kreuter M, Ehlers-Tenenbaum S, Palmowski K. et al. Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS One 2016; 11: e0151425
    CrossrefPubMedGoogle Scholar
  • 58 Allaix ME, Fisichella PM, Noth I. et al. The Pulmonary Side of Reflux Disease: from Heartburn to Lung Fibrosis. J Gastrointest Surg 2013; 17: 1526-1535
    CrossrefPubMedGoogle Scholar
  • 59 Lee JS, Song JW, Wolters PJ. et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2012; 39: 352-358
    CrossrefPubMedGoogle Scholar
  • 60 Raghu G. Idiopathic pulmonary fibrosis: increased survival with “gastroesophageal reflux therapy”: fact or fallacy?. Am J Respir Crit Care Med 2011; 184: 1330-1332
    CrossrefPubMedGoogle Scholar
  • 61 Lee JS, Collard HR, Anstrom KJ. et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013; 1: 369-376
    CrossrefPubMedGoogle Scholar
  • 62 Raghu G, Freudenberger TD, Yang S. et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27: 136-142
    CrossrefPubMedGoogle Scholar
  • 63 Kreuter M, Wuyts W, Renzoni E. et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 2016; 4: 381-389
    CrossrefPubMedGoogle Scholar
  • 64 Kreuter M, Spagnolo P, Wuyts W. et al. Antacid therapy and disease progression in patients with IPF who received pirfenidone. Respiration 2017; DOI: 10.1159/000468546.
    CrossrefPubMedGoogle Scholar
  • 65 Raghu G, Crestani B, Bailes Z. et al. Effect of anti-acid medication on reduction in FVC decline with nintedanib. Eur Respir J 2015; 46 (Suppl. 59) OA450
    PubMedGoogle Scholar
  • 66 Costabel U, Albera C, Bradford WZ. et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 198-205
    PubMedGoogle Scholar
  • 67 Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev 2015; 24: 58-64
    CrossrefPubMedGoogle Scholar
  • 68 Okuda R, Hagiwara E, Baba T. et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 2013; 107: 1431-1437
    CrossrefPubMedGoogle Scholar
  • 69 Chaudhuri N, Duck A, Frank R. et al. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med 2014; 108: 224-226
    CrossrefPubMedGoogle Scholar
  • 70 Arai T, Inoue Y, Sasaki Y. et al. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig 2014; 52: 136-143
    CrossrefPubMedGoogle Scholar
  • 71 Taguchi Y, Ebina M, Hashimoto S. et al. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan. Respir Investig 2015; 53: 279-287
    CrossrefPubMedGoogle Scholar
  • 72 King CS, Nathan SD. Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2015; 21: 479-489
    PubMedGoogle Scholar
  • 73 du Bois 1 RM, Weycker D, Albera C. et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389
    CrossrefPubMedGoogle Scholar
  • 74 Behr J, Bonella F, Bonnet R. et al. Position Paper: Significance of the Forced Vital Capacity in Idiopathic Pulmonary Fibrosis. Pneumologie 2015; 69: 455-458
    Article in Thieme ConnectPubMedGoogle Scholar
  • 75 Nathan SD. et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 2016; 71: 429-435
    CrossrefPubMedGoogle Scholar
  • 76 Richeldi L, Azuma A, Selman M. et al. Twenty-four week decline in forced vital capacity predicts mortality at week 52 in the INPULSIS® trials. Eur Respir J 2016; OA1814
    PubMedGoogle Scholar
  • 77 Milger K, Kneidinger N, Neurohr C. et al. Switching to nintedanib after discontinuation of pirfenidone dueto adverse events in IPF. Eur Respir J 2015; 46: 1217-1221
    CrossrefPubMedGoogle Scholar
  • 78 Wuyts WA, Antoniou KM, Borensztajn K. et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respir Med 2014; 2: 933-942
    CrossrefPubMedGoogle Scholar
  • 79 Behr J, Bendstrup E, Crestani B. et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 2016; 4: 445-453
    CrossrefPubMedGoogle Scholar
  • 80 Ogura T, Taniguchi H, Azuma A. et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1382-1392
    CrossrefPubMedGoogle Scholar
  • 81 Raghu G, Collard HR, Egan JJ. et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824
    CrossrefPubMedGoogle Scholar
  • 82 Lettieri CJ, Veerappan GR, Helman DL. et al. Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest 2005; 127: 1600-1605
    CrossrefPubMedGoogle Scholar
  • 83 Park JH, Kim DK, Kim DS. et al. Mortality and risk factors for surgical lung biopsy in patients with idiopathic pulmonary fibrosis. Eur J Cardiothorac Surg 2007; 31: 1115-1119
    CrossrefPubMedGoogle Scholar
  • 84 Hutchinson JP, Fogarty AW, McKeever TM. et al. In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011. American journal of respiratory and critical care medicine 2016; 193: 1161-1167
    CrossrefPubMedGoogle Scholar
  • 85 Casoni GL, Tomassetti S, Cavazza A. et al. Cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One 2014; 09: e86716
    CrossrefPubMedGoogle Scholar
  • 86 Tomassetti S, Wells AU, Costabel U. et al. Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Am J Rrespir Crit Care Med 2016; 193: 745-752
    PubMedGoogle Scholar
  • 87 Ravaglia C, Bonifazi M, Wells AU. et al. Safety and diagnostic yield of transbronchial lung cryobiopsy in diffuse parenchymal lung diseases: A comparative study versus video-assisted thoracoscopic lung biopsy and a systematic review of the literature. Respiration 2016; 91: 215-227
    CrossrefPubMedGoogle Scholar
  • 88 Poletti V, Ravaglia C, Tomassetti S. Transbronchial cryobiopsy in diffuse parenchymal lung diseases. Current Opinion in Pulmonary Medicine 2016; 22: 289-296
    CrossrefPubMedGoogle Scholar
  • 89 Poletti V, Ravaglia C, Gurioli C. et al. Invasive diagnostic techniques in idiopathic interstitial pneumonias. Respirology 2016; 21: 44-50
    CrossrefPubMedGoogle Scholar